Clearance of Persistent SARS-CoV-2 RNA Detection in a NFκB-Deficient Patient in Association with the Ingestion of Human Breast Milk: A Case Report
Authors:
- Janine S. SabinoJSJanine S. Sabino
- Mariene R. AmorimMAMariene R. Amorim
- William M. de SouzaWSWilliam M. de Souza
- Lia F. MaregaLMLia F. Marega
- Luciana S. MofattoLMLuciana S. Mofatto
- Daniel A. Toledo-TeixeiraDTDaniel A. Toledo-Teixeira
- Julia ForatoJFJulia Forato
- Rodrigo G. StabeliRodrigo G. Stabeli
- Maria Laura CostaMCMaria Laura Costa
- Fernando R. SpilkiFernando R. Spilki
- Ester C. SabinoESEster C. Sabino
- Nuno R. FariaNFNuno R. Faria
Open Access
Abstract
Currently, there are no evidence-based treatment options for long COVID-19, and it is known that SARS-CoV-2 can persist in part of the infected patients, especially those with immunosuppression. Since there is a robust secretion of SARS-CoV-2-specific highly-neutralizing IgA antibodies in breast milk, and because this immunoglobulin plays an essential role against respiratory virus infection in mucosa cells, being, in addition, more potent in neutralizing SARS-CoV-2 than IgG, here we report the clinical course of an NFκB-deficient patient chronically infected with the SARS-CoV-2 Gamma variant, who, after a non-full effective treatment with plasma infusion, received breast milk from a vaccinated mother by oral route as treatment for COVID-19. After such treatment, the symptoms improved, and the patient was systematically tested negative for SARS-CoV-2. Thus, we hypothesize that IgA and IgG secreted antibodies present in breast milk could be useful to treat persistent SARS-CoV-2 infection in immunodeficient patients.Keywords
Funding Information
- São Paulo Research Foundation (2016/00194-8, 2020/04558-0, 2018/14372-0, 2266/20, 01.20.0003.00, 01.20.0029.000462/20, 404096/2020-4, 401977/2020, MR/S0195/1, FAPESP 2018/14389-0, 305628/2020-8, AI120942, 88887.356527/2019-00, 88887.513498/2020-00, 141844/2019-1, 382630/2021-1)
- Fundo de Apoio ao Ensino, Pesquisa e Extensão of UNICAMP (2016/00194-8, 2020/04558-0, 2018/14372-0, 2266/20, 01.20.0003.00, 01.20.0029.000462/20, 404096/2020-4, 401977/2020, MR/S0195/1, FAPESP 2018/14389-0, 305628/2020-8, AI120942, 88887.356527/2019-00, 88887.513498/2020-00, 141844/2019-1, 382630/2021-1)
- Financier of Studies and Projects [FINEP] (2016/00194-8, 2020/04558-0, 2018/14372-0, 2266/20, 01.20.0003.00, 01.20.0029.000462/20, 404096/2020-4, 401977/2020, MR/S0195/1, FAPESP 2018/14389-0, 305628/2020-8, AI120942, 88887.356527/2019-00, 88887.513498/2020-00, 141844/2019-1, 382630/2021-1)
- Rede Vírus/MCTI (2016/00194-8, 2020/04558-0, 2018/14372-0, 2266/20, 01.20.0003.00, 01.20.0029.000462/20, 404096/2020-4, 401977/2020, MR/S0195/1, FAPESP 2018/14389-0, 305628/2020-8, AI120942, 88887.356527/2019-00, 88887.513498/2020-00, 141844/2019-1, 382630/2021-1)
- Brazilian National Council for Scientific and Technological Development (CNPq) (2016/00194-8, 2020/04558-0, 2018/14372-0, 2266/20, 01.20.0003.00, 01.20.0029.000462/20, 404096/2020-4, 401977/2020, MR/S0195/1, FAPESP 2018/14389-0, 305628/2020-8, AI120942, 88887.356527/2019-00, 88887.513498/2020-00, 141844/2019-1, 382630/2021-1)
- Medical Research Council (2016/00194-8, 2020/04558-0, 2018/14372-0, 2266/20, 01.20.0003.00, 01.20.0029.000462/20, 404096/2020-4, 401977/2020, MR/S0195/1, FAPESP 2018/14389-0, 305628/2020-8, AI120942, 88887.356527/2019-00, 88887.513498/2020-00, 141844/2019-1, 382630/2021-1)
- CNPq (2016/00194-8, 2020/04558-0, 2018/14372-0, 2266/20, 01.20.0003.00, 01.20.0029.000462/20, 404096/2020-4, 401977/2020, MR/S0195/1, FAPESP 2018/14389-0, 305628/2020-8, AI120942, 88887.356527/2019-00, 88887.513498/2020-00, 141844/2019-1, 382630/2021-1)
- Global Virus Network fellowship (2016/00194-8, 2020/04558-0, 2018/14372-0, 2266/20, 01.20.0003.00, 01.20.0029.000462/20, 404096/2020-4, 401977/2020, MR/S0195/1, FAPESP 2018/14389-0, 305628/2020-8, AI120942, 88887.356527/2019-00, 88887.513498/2020-00, 141844/2019-1, 382630/2021-1)
- NIH (2016/00194-8, 2020/04558-0, 2018/14372-0, 2266/20, 01.20.0003.00, 01.20.0029.000462/20, 404096/2020-4, 401977/2020, MR/S0195/1, FAPESP 2018/14389-0, 305628/2020-8, AI120942, 88887.356527/2019-00, 88887.513498/2020-00, 141844/2019-1, 382630/2021-1)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (2016/00194-8, 2020/04558-0, 2018/14372-0, 2266/20, 01.20.0003.00, 01.20.0029.000462/20, 404096/2020-4, 401977/2020, MR/S0195/1, FAPESP 2018/14389-0, 305628/2020-8, AI120942, 88887.356527/2019-00, 88887.513498/2020-00, 141844/2019-1, 382630/2021-1)
- CNPq (2016/00194-8, 2020/04558-0, 2018/14372-0, 2266/20, 01.20.0003.00, 01.20.0029.000462/20, 404096/2020-4, 401977/2020, MR/S0195/1, FAPESP 2018/14389-0, 305628/2020-8, AI120942, 88887.356527/2019-00, 88887.513498/2020-00, 141844/2019-1, 382630/2021-1)
This publication has 39 references indexed in Scilit:
- Comparison of the GeneFinderTM COVID-19 Plus RealAmp Kit on the sample-to-result Platform ELITe InGenius to the national reference method: An added value of N gene target detection?Journal of Clinical Virology, 2020
- Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutationsJournal of Allergy and Clinical Immunology, 2020
- Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCREurosurveillance, 2020
- Robust and persistent SARS-CoV-2 infection in the human intestinal brush border expressing cellsEmerging Microbes & Infections, 2020
- Microbiota-derived acetate protects against respiratory syncytial virus infection through a GPR43-type 1 interferon responseNature Communications, 2019
- Nextstrain: real-time tracking of pathogen evolutionBioinformatics, 2018
- The Effect of Exclusive Breast-feeding on Respiratory Illness in Young Infants in a Maternal Immunization Trial in BangladeshThe Pediatric Infectious Disease Journal, 2013
- The Sequence Alignment/Map format and SAMtoolsBioinformatics, 2009
- Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirusJournal of General Virology, 2006
- Secretory IgA antibodies provide cross‐protection against infection with different strains of influenza B virusJournal of Medical Virology, 2004